MEDICA in Düsseldorf, a leading medical B2B trade fair, has once again become a global highlight from 13-16 November this year. Kehua Bio-engineering (hereinafter called “KHB”) made its appearance at this grand event, in collaboration with subsidiary corporation Tianlong Technology, showcasing the latest IVD solutions to the global market.

Intelligent and innovative products of laboratory medicine were demonstrated by KHB team in this exhibition, including Polaris c1000 Automatic Modular Clinical Chemistry Analysis System and ZY-260 Fully Automatic Biochemical Analysis System. The rich item menu and customized instrument combination solutions were well received, which meet the needs of sustainable development of laboratory.

Subsidiary Guangdong Focus Diagnostics Co., Ltd. participated in the conference with two star POCT products, including Pangu MF200 biochemistry and coagulation machine and Houyi CL100 chemiluminescence immunometer, which cover routine biochemistry package, coagulation of up to seven items, myocardial, inflammation, swelling markers, endocrine and so on, and the related models are compatible with the pet hospitals with more than 95% of the relevant testing needs, which have gained wide attention at home and abroad.

Tianlong showcased excellent products and solutions including iGeneCase 1600 Diagnostics-in-a-Suitcase, Panall 8000 all-in-one molecular diagnosis system, and PANA 9600X Automated Nucleic Acid Workstation, as well as a variety of nucleic acid extraction systems and PCR systems, supporting lab detection in automation, informatics, and intelligence. The nucleic acid extraction and PCR testing reagents cover the detection of various common diseases, meeting the detection needs in clinical diagnosis, epidemic monitoring, food safety, forensic identification, and scientific research etc.

During the event, KHB engaged in insights exchanges and cooperative discussions with experts, scholars, as well as companies from around the world, and also present visitors with pioneering technologies and innovative products, as well as the latest research achievements and application cases in molecular diagnostics.

Thanks to the participation in MEDICA 2023, KHB has gained valuable experience and feedback, enhanced market influence, and expanded international cooperation opportunities. In the future, KHB will continue to develop research and development efforts and innovations to the medical industry.